Indication
Acute Myeloid Leukemia with Gene Mutations
2 clinical trials
5 products
Clinical trial
A Phase 1, Open-label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)Status: Not yet recruiting, Estimated PCD: 2025-09-01
Product
ZE46-0134Clinical trial
A Phase I Trial of Revumenib in Combination With 7+3 (7 Days of Cytarabine and 3 Days of Daunorubicin) + Midostaurin Induction Chemotherapy for the Frontline Treatment of NPM1 and FLT3 Mutated AMLStatus: Not yet recruiting, Estimated PCD: 2026-03-02
Product
RevumenibProduct
MidostaurinProduct
CytarabineProduct
Daunorubicin